Elifnaz Celik

Elifnaz Celik

Auto-generated profile, based on publicly available information

Elifnaz Celik

Department of Molecular Biology‐Genetics & Biotechnology Istanbul Technical University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
GPGundula Povysil
Gundula Povysil
JKJack A. Kosmicki
Jack A. Kosmicki
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
TDTheodore Drivas
Theodore Drivas
JRJ Brent Richards
J Brent Richards
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

13 July 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
IAIzzet Mehmet Akcay
Izzet Mehmet Akcay
ECElifnaz Celik
Elifnaz Celik
NANihat Bugra Agaoglu
Nihat Bugra Agaoglu
GAGizem Alkurt
Gizem Alkurt
TATugba Kizilboga Akgun
Tugba Kizilboga Akgun
HDHamdi Levent Doganay
Hamdi Levent Doganay

25 March 2024 in The American Journal of Human Genetics
Verified
Journal Article
Open access
MQMathieu Quinodoz
Mathieu Quinodoz
KKKarolina Kaminska
Karolina Kaminska
FCFrancesca Cancellieri
Francesca Cancellieri
JHJi Hoon Han
Ji Hoon Han
VPVirginie Peter
Virginie Peter
CRCarlo Rivolta
Carlo Rivolta
Copy-number variants (CNVs) play a substantial role in the molecular pathogenesis of hereditary disease and cancer, as well as in normal human interindividual variation. However, they are still rather difficult to identify in mainstream sequencing projects, especially involving exome sequencing, because they often occur in DNA regions that are not targeted for analysis. To overcome this problem, we developed OFF-PEAK, a user-friendly CNV detection tool that builds on a denoising approach and the use of "off-target" DNA reads, which are usually discarded by sequencing pipelines. We benchmarked OFF-PEAK on data from targeted sequencing of 96 cancer samples, as well as 130 exomes of individuals with inherited retinal disease from three different populations. For both sets of data, OFF-PEAK demonstrated excellent performance (>95% sensitivity and >80% specificity vs. experimental validation) in detecting CNVs from in silico data alone, indicating its immediate applicability to molecular diagnosis and genetic research.

17 July 2018 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
ECElifnaz Celik
Elifnaz Celik
KTKubra Ermis Tekkus
Kubra Ermis Tekkus
IAIzzet Mehmet Akcay
Izzet Mehmet Akcay
GSGizem Alkurt Sal
Gizem Alkurt Sal
FEFikret Ezberci
Fikret Ezberci
HDHamdi Levent Doganay
Hamdi Levent Doganay
Key Clinical Message: We used a multi‐gene panel testing to identify the germline variants in a mother‐daughter pair with early‐onset breast cancer, and detected one pathogenic protein‐truncating variant in BRCA 2 . Our results highlight the importance of genetic testing in identifying the pathogenic mutation running in cancer families.

8 February 2026 in Human Genomics
Verified
Journal Article
Open access
NCNisan Denizce Can
Nisan Denizce Can
IAIzzet Mehmet Akcay
Izzet Mehmet Akcay
ECElifnaz Celik
Elifnaz Celik
CCCeren Ciftci
Ceren Ciftci
BUBusra Unal
Busra Unal
GDGizem Dinler Doganay
Gizem Dinler Doganay
The online version contains supplementary material available at 10.1186/s40246-026-00915-0.